When will Agenerase be approved, and how will Vertex make money from it?

The FDA's review of Agenerase's NDA, filed October 15, 1998 under fast-track designation, is expected to be completed by mid-April 1999. Approval is not guaranteed and may depend on the Phase III studies. Glaxo Wellcome holds exclusive rights outside the Far East and will market the drug, while Vertex earns royalties on sales and shares co-promotion. Kissei holds Far East rights.

Why did Vertex's net loss increase in 1998?

Total costs rose to $77.5M from $63.6M. R&D increased to $58.7M from $51.6M on added research staff, a new U.K. research site, and expanded development infrastructure. G&A grew to $18.1M from $11.4M due to headcount, IP legal expenses, and pre-launch marketing for Agenerase. Revenue was essentially flat, so the loss widened to $33.1M.

Does Vertex have enough cash to fund its operations?

At December 31, 1998, Vertex held $245.7M in cash and investments. Management plans to fund operations through Agenerase royalties, existing cash, interest income, collaboration payments, and equipment financing. The company notes that if these sources prove insufficient, it may need to raise additional capital through equity or debt offerings, which could dilute shareholders, or through new partnerships that may require giving up certain rights.

What are the biggest risks to Vertex's business?

The main risks include the uncertain regulatory outcome and market acceptance of Agenerase, faced with four competing HIV protease inhibitors already on the market. Collaborative partners can terminate their agreements, including Glaxo Wellcome on 12 months' notice. The company has no sales force or large-scale manufacturing experience and relies on third-party manufacturers. Patent protection is uncertain, and Chiron has filed an infringement suit over hepatitis C protease research that the company calls without merit.

VRTX 10-K FY1998 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed March 30, 1999. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals' 1998 10-K describes a company still in the pre-revenue, clinical-stage phase, built around its structure-based drug design platform.

Its lead product, Agenerase (amprenavir), an HIV protease inhibitor partnered with Glaxo Wellcome, had its New Drug Application filed in October 1998 under FDA fast-track designation, with review expected to conclude around mid-April 1999. Vertex has not yet received material product sales revenue. Upon approval, it expects royalty income on Glaxo Wellcome's sales, and it is also co-promoting the drug.

Approval is not assured, and the filing notes that full approval depends on ongoing Phase III studies. Financially, 1998 total revenues were $44.4 million^a, roughly flat versus $43.8 million in 1997. Collaborative revenue fell slightly to $29.1 million, while investment income rose to $15.3 million.

Research and development spending increased to $58.7 million and G&A rose sharply to $18.1 million^b, driven by headcount growth, legal costs for IP expansion, and pre-launch marketing. The net loss widened to $33.1 million ($1.31 per share) from $19.8 million ($0.82 per share). Cash and investments declined to $245.7 million from $279.7 million, and management expects continued losses in 1999 and possibly beyond, even if Agenerase royalties materialize.

Cash burn was $31.1 million^c from operations, and the company expressed no concern about near-term funding. Investors should weigh the binary nature of the Agenerase regulatory decision against a broad but early pipeline.

That pipeline includes Incel for multidrug resistance in cancer (Phase II), VX-497 for psoriasis and hepatitis C (Phase II), timcodar for diabetic neuropathy (Phase II), and VX-740 and VX-745 for inflammatory disease (Phase I). Key risks include dependence on collaborators, with Glaxo Wellcome able to terminate on 12 months' notice; a pending chiron patent infringement suit related to hepatitis C protease research; and the absence of internal manufacturing and sales capabilities.

02—Key points

Key Highlights

Agenerase (amprenavir), the lead HIV protease inhibitor partnered with Glaxo Wellcome, had its NDA filed October 15, 1998, with FDA review under fast-track designation expected to finish by mid-April 1999; Vertex will receive royalties on sales.
1998 total revenues were $44.4M, nearly flat versus $43.8M in 1997, with investment income of $15.3M making up about one-third of the total.
The net loss widened to $33.1M ($1.31 per share) from $19.8M ($0.82 per share), driven by R&D spending of $58.7M and G&A growth to $18.1M ahead of a product launch.
Cash, cash equivalents and investments totaled $245.7M at year-end 1998, down $34.0M from 1997, with operating cash burn of $31.1M.
The company expects to incur a loss in 1999 and may continue to lose money beyond 1999, even if royalties on Agenerase are realized.
The pipeline spans multiple programs: Incel (MDR, Phase II), VX-497 (IMPDH, Phase II), timcodar (neurophilin, Phase II), VX-740 (ICE, Phase I completed), and VX-745 (p38 MAP kinase, Phase I started March 1999).
Material risks include Glaxo Wellcome's right to terminate on 12 months' notice, a Chiron patent infringement lawsuit over hepatitis C protease research, and no internal sales or large-scale manufacturing experience.

03—Questions

Frequently Asked Questions

When will Agenerase be approved, and how will Vertex make money from it?
The FDA's review of Agenerase's NDA, filed October 15, 1998 under fast-track designation, is expected to be completed by mid-April 1999. Approval is not guaranteed and may depend on the Phase III studies. Glaxo Wellcome holds exclusive rights outside the Far East and will market the drug, while Vertex earns royalties on sales and shares co-promotion. Kissei holds Far East rights.
Why did Vertex's net loss increase in 1998?
Total costs rose to $77.5M from $63.6M. R&D increased to $58.7M from $51.6M on added research staff, a new U.K. research site, and expanded development infrastructure. G&A grew to $18.1M from $11.4M due to headcount, IP legal expenses, and pre-launch marketing for Agenerase. Revenue was essentially flat, so the loss widened to $33.1M.
Does Vertex have enough cash to fund its operations?
At December 31, 1998, Vertex held $245.7M in cash and investments. Management plans to fund operations through Agenerase royalties, existing cash, interest income, collaboration payments, and equipment financing. The company notes that if these sources prove insufficient, it may need to raise additional capital through equity or debt offerings, which could dilute shareholders, or through new partnerships that may require giving up certain rights.
What are the biggest risks to Vertex's business?
The main risks include the uncertain regulatory outcome and market acceptance of Agenerase, faced with four competing HIV protease inhibitors already on the market. Collaborative partners can terminate their agreements, including Glaxo Wellcome on 12 months' notice. The company has no sales force or large-scale manufacturing experience and relies on third-party manufacturers. Patent protection is uncertain, and Chiron has filed an infringement suit over hepatitis C protease research that the company calls without merit.

04—Continue

← View all 10-K filings